Literature DB >> 32533268

The Role of New IL-1 Family Members (IL-36 and IL-38) in Atopic Dermatitis, Allergic Asthma, and Allergic Rhinitis.

Miranda Sin-Man Tsang1,2, Xiaoyu Sun1, Chun Kwok Wong3,4,5.   

Abstract

PURPOSE OF REVIEW: Since the discovery of its very first member in 1974, the IL-1 family has expanded into a group of 11 potent molecules which are essential in both innate and acquired immunity. Pro-inflammatory cytokines IL-36α, IL-36β, and IL-36γ and their receptor antagonists IL-36Ra and IL-38, which belong to the IL-36 subfamily, are some of the most recently identified members. Recent studies show that these members possess pro-inflammatory and anti-inflammatory activities and may take part in the pathogenesis of allergy. In this review, the involvement and importance of these newly described IL-1 family members in the most common allergic diseases, i.e., atopic dermatitis (AD), allergic asthma, and allergic rhinitis, will be discussed. RECENT
FINDINGS: Dysregulation of IL-36 and IL-38 was observed in the skin and respiratory tract of AD, allergic rhinitis, and allergic asthma individuals. Although the upregulation in IL-36α and IL-36γ observed in the lesional skin of AD patients was unexpectedly small, IL-36 may play an important role in AD pathogenesis especially upon Staphylococcus aureus colonization. While IL-36γ regulates eosinophils to induce an inflammatory response in allergic rhinitis, IL-36α was found to regulate Th17 immunity. IL-36 receptor antagonists, IL-36Ra and IL-38, however, both show promising anti-inflammatory activities against allergic asthma. Of note, IL-38 in allergic asthmatic children is significantly lower than their healthy counterparts, while the anti-inflammatory effects of IL-38 in allergic asthma exacerbation upon viral-like infection were demonstrated in in vitro, HDM-induced, and humanized mice models. Dysregulated expression of IL-36 and IL-38 observed in allergic patients and mice models revealed that they may have essential roles in the pathogenesis in AD, allergic rhinitis, and allergic asthma, especially during the host defense against pathogens at inflammatory sites. Their receptor antagonists, IL-36Ra and IL-38, could also be promising biologics in the control of allergy. Since allergic diseases are phenotypically complex, contradictory data obtained in different studies may be explained if further stratification of disease endotypes is explored. Genetically modified mice model and investigation in anti-IL-36 treatment may be useful to characterize the therapeutic potential of these cytokines in the regulation of allergy in the future.

Entities:  

Keywords:  Allergic asthma; Allergic rhinitis; Atopic dermatitis; IL-36; IL-38

Year:  2020        PMID: 32533268     DOI: 10.1007/s11882-020-00937-1

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  13 in total

1.  IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation.

Authors:  Xinhui Ni; Yi Xu; Wang Wang; Baida Kong; Jian Ouyang; Jiwei Chen; Man Yan; Yawei Wu; Qi Chen; Xinxin Wang; Hongquan Li; Xiaoguang Gao; Hongquan Guo; Lian Cui; Zeyu Chen; Yuling Shi; Ronghui Zhu; Wei Li; Tieliu Shi; Lin-Fa Wang; Jinling Huang; Chen Dong; Yuping Lai
Journal:  Nat Immunol       Date:  2022-10-21       Impact factor: 31.250

Review 2.  Immunomodulatory Role of Staphylococcus aureus in Atopic Dermatitis.

Authors:  Ethan Jachen Chung; Chia-Hui Luo; Christina Li-Ping Thio; Ya-Jen Chang
Journal:  Pathogens       Date:  2022-03-30

3.  The chemokine CX3CL1/fractalkine regulates immunopathogenesis during fungal-associated allergic airway inflammation.

Authors:  Matthew S Godwin; MaryJane Jones; Jonathan P Blackburn; Zhihong Yu; Sadis Matalon; Annette T Hastie; Deborah A Meyers; Chad Steele
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-12-16       Impact factor: 5.464

4.  Chitinase 3-like-1 protects airway function despite promoting type 2 inflammation during fungal-associated allergic airway inflammation.

Authors:  Joseph J Mackel; Jaleesa M Garth; MaryJane Jones; Diandra A Ellis; Jonathan P Blackburn; Zhihong Yu; Sadis Matalon; Miranda Curtiss; Frances E Lund; Annette T Hastie; Deborah A Meyers; Chad Steele
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-02-03       Impact factor: 6.011

5.  Interleukin-38 ameliorates poly(I:C) induced lung inflammation: therapeutic implications in respiratory viral infections.

Authors:  Xun Gao; Paul Kay Sheung Chan; Grace Chung Yan Lui; David Shu Cheong Hui; Ida Miu-Ting Chu; Xiaoyu Sun; Miranda Sin-Man Tsang; Ben Chung Lap Chan; Christopher Wai-Kei Lam; Chun-Kwok Wong
Journal:  Cell Death Dis       Date:  2021-01-07       Impact factor: 8.469

6.  Low serum interleukin-38 levels in patients with Graves' disease and Hashimoto's thyroiditis.

Authors:  Jialu Xu; Guoqing Huang; Linjie Weng; Luping Gong; Yushan Mao; Yan Li; Mingcai Li
Journal:  J Clin Lab Anal       Date:  2021-11-19       Impact factor: 2.352

Review 7.  Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study.

Authors:  Abdolreza Esmaeilzadeh; Nazila Bahmaie; Elham Nouri; Mohammad Javad Hajkazemi; Maryam Zareh Rafie
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

Review 8.  Skin-Expressing lncRNAs in Inflammatory Responses.

Authors:  Alanna Shefler; Matthew T Patrick; Rachael Wasikowski; Jiahan Chen; Mrinal K Sarkar; Johann E Gudjonsson; Lam C Tsoi
Journal:  Front Genet       Date:  2022-04-26       Impact factor: 4.772

9.  A novel function of NLRP3 independent of inflammasome as a key transcription factor of IL-33 in epithelial cells of atopic dermatitis.

Authors:  Jie Zheng; Lu Yao; Yijing Zhou; Xiaoqun Gu; Can Wang; Kaifan Bao; Yang Sun; Min Hong
Journal:  Cell Death Dis       Date:  2021-09-24       Impact factor: 8.469

Review 10.  Role of Epigenetics in the Pathogenesis, Treatment, Prediction, and Cellular Transformation of Asthma.

Authors:  Binaya Wasti; Shao-Kun Liu; Xu-Dong Xiang
Journal:  Mediators Inflamm       Date:  2021-09-15       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.